James L LaBelle
Overview
Explore the profile of James L LaBelle including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
553
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jiang S, Tian Y, Nicolaescu V, Mansurov A, Randall G, Tirrell M, et al.
Pept Sci (Hoboken)
. 2025 Jan;
116(6.
PMID: 39866902
The COVID-19 pandemic drove a uniquely fervent pursuit to explore the potential of peptide, antibody, protein, and small-molecule based antiviral agents against severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2). The interaction...
2.
He G, Belmont E, Karrison T, Stock W, LaBelle J, Kosuri S, et al.
Ann Transl Med
. 2024 Jun;
12(3):49.
PMID: 38911560
Background: The somatic mutation of fms-like tyrosine kinase 3 () in acute myeloid leukemia (AML) is associated with increased risk of relapse and lower survival rates. FLT3i as maintenance after...
3.
Liao R, Hsu J, Aboelella N, McKeever J, Thomas-Toth A, Koh A, et al.
Cancer Immunol Res
. 2024 May;
12(8):1074-1089.
PMID: 38810242
The specific BCL-2 small molecule inhibitor venetoclax induces apoptosis in a wide range of malignancies, which has led to rapid clinical expansion in its use alone and in combination with...
4.
Schnorenberg M, Hawley K, Thomas-Toth A, Watkins E, Tian Y, Ting J, et al.
ACS Nano
. 2023 Sep;
17(23):23374-23390.
PMID: 37688780
Diffuse large B-cell lymphoma (DLBCL) remains a formidable diagnosis in need of new treatment paradigms. In this work, we elucidated an opportunity for therapeutic synergy in DLBCL by reactivating tumor...
5.
Sharma A, Boelens J, Cancio M, Hankins J, Bhad P, Azizy M, et al.
N Engl J Med
. 2023 Aug;
389(9):820-832.
PMID: 37646679
Background: Sickle cell disease is caused by a defect in the β-globin subunit of adult hemoglobin. Sickle hemoglobin polymerizes under hypoxic conditions, producing deformed red cells that hemolyze and cause...
6.
Rinella S, Bell H, Hess N, Hoang N, Nguyen T, Turicek D, et al.
bioRxiv
. 2023 Jun;
PMID: 37333339
Treatment of relapsed/refractory B cell acute lymphoblastic leukemia (B-ALL) remains a challenge, particularly in patients who do not respond to traditional chemotherapy or immunotherapy. The objective of this study was...
7.
8.
Hawley K, Eclov R, Schnorenberg M, Tian Y, Shah R, Thomas-Toth A, et al.
Proc Natl Acad Sci U S A
. 2022 Oct;
119(42):e2209044119.
PMID: 36227917
Despite continuing advances in the development of novel cellular-, antibody-, and chemotherapeutic-based strategies to enhance immune reactivity, the presence of regulatory T cells (Treg cells) remains a complicating factor for...
9.
Tran M, Hasan Y, Wang A, Yenice K, Partouche J, Stock W, et al.
Blood Adv
. 2022 Jul;
7(3):285-292.
PMID: 35851593
Relapse after allogeneic stem cell transplantation (allo-SCT) remains the primary cause of treatment failure. A second SCT can result in long-term survival in a subset of patients, but the relapse...
10.
Desai A, Applebaum M, Karrison T, Oppong A, Yuan C, Berg K, et al.
Cancer
. 2022 Jun;
128(15):2967-2977.
PMID: 35665495
Background: High-risk neuroblastoma patients with end-induction residual disease commonly receive post-induction therapy in an effort to increase survival by improving the response before autologous stem cell transplantation (ASCT). The authors...